UT Horizon Fund

UT Horizon Fund

UT Horizon Fund is the venture fund of the University of Texas System. It aims to improve the commercialization of technologies out of research at UT System institutions

UT Horizon Fund is a venture capital firm in Austin that prefers to invest in companies within the technology sector. Founded 2011 in Austin, Texas, the firm invests in early stage and late stage ventures. The notable investment portfolio of UT Horizon Fundincludes Cerebri AI, GenXComm, Astrocyte Pharmaceuticals, Lung Therapeutics, Alafair Biosciences, Decisio Health, and MicroTransponder. As of January 2020, UT Horizon Fund has made 30 investments and 6 exits. Their most recent investment was on Dec 4, 2019, when Cerebri AI raised $7M.

Timeline

2011

Founded

Funded Companies

Company
Description
Industry
Website
Location
Lung Therapeutics

Therapeutics for lung injury and disease company

Biotechnology
Austin, Texas
Aeglea BioTherapeutics

Aeglea BioTherapeutics is a Austin, Texas-based pharmaceutical company developing drugs for the treatment of tumors.

Biotechnology
Austin, Texas
Cerebri AI

Artificial Intelligence company

Machine learning
Austin, Texas
Generation X Communication

Generation X Communication is an Austin, Texas-based company founded in 2016 by Hardik Jain.

Microprocessor
Austin, Texas
4 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Bryan Allinson

Founder and Executive Director

Carlos Kemeny

Director for Entrepreneurship Network

Gus Johnson

Assistant Director

Julie Goonewardene

Managing Director

Matt Sorenson

Investment Analyst

Nick Tulloh

Senior Investment Analyst

Suruchi Parwal

Senior Investment Analyst

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Alafair Biosciences

Astrocyte Pharmaceuticals

Cerebri AI

Decisio Health

GenXComm

Lung Therapeutics

Lung Therapeutics

MicroTransponder

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.